;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Tralokinumab: Phase III started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Tralokinumab (CAT-354) Business: Inflammation Molecular target: Interleukin-13 (IL-13) Description: Human IgG4 mAb against IL-13 Indication: Treat uncontrolled,…

    Published on 9/1/2014
  • TRV734: Phase I started

    Trevena Inc. (NASDAQ:TRVN), King of Prussia, Pa. Product: TRV734 Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR) Description: G protein-biased mu opioid receptor (OPRM1; MOR) ligand Indication: …

    Published on 9/1/2014
  • Vantictumab: Phase Ib ongoing

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Vantictumab (anti-Frizzled) (OMP-18R5) Business: Cancer Molecular target: Frizzled homolog 7 (FZD7) Description: Human HuCAL mAb targeting the …

    Published on 9/1/2014
  • VC-01: Phase I/II start

    ViaCyte Inc., San Diego, Calif. Product: VC-01 Business: Endocrine/Metabolic Molecular target: NA Description: ViaCytes PEC-01 cells, which are human embryonic stem cells (hESCs)-derived pancreatic progenitor cells, …

    Published on 9/1/2014
  • Xalkori crizotinib: Phase III started

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Xalkori crizotinib (PF-02341066) Business: Cancer Molecular target: c-Met receptor tyrosine kinase; Anaplastic lymphoma kinase (ALK) Description: Dual inhibitor of c-Met …

    Published on 9/1/2014
  • Xiaflex: Phase II started

    Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL), Chesterbrook, Pa. BioSpecifics Technologies Corp. (NASDAQ:BSTC), Lynbrook, N.Y. Product: Xiaflex ( XiapexEU) collagenase clostridium histolyticum Business: Other Molecular …

    Published on 9/1/2014
  • Ztilido: Pivotal trial completed enrollment

    Scilex Pharmaceuticals Inc., West Chester, Pa. Product: Ztilido Business: Neurology Molecular target: NA Description: Transdermal lidocaine patch formulation Indication: Treat pain associated with post-herpetic …

    Published on 9/1/2014
  • ALKS 5461: Phase III started

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: ALKS 5461 Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR); Kappa opioid receptor (OPRK1) (KOR) Description: Combination of ALKS 33, a mu opioid…

    Published on 8/18/2014
  • Benralizumab: Phase III started

    Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Benralizumab (KHK4563, MEDI-563) (formerly BIW-8405) Business: Pulmonary Molecular target: Interleukin-5 (…

    Published on 8/18/2014
  • Benralizumab: Phase III started

    Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Benralizumab (KHK4563, MEDI-563) (formerly BIW-8405) Business: Pulmonary Molecular target: Interleukin-5 (…

    Published on 8/18/2014
  • Bertilimumab: Phase II started

    iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc. (OTCQX:IMNP; SSE:IMNP), Tarrytown, N.Y. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bertilimumab (iCo-008, CAT-…

    Published on 8/18/2014
  • Clonidine: Phase III amended

    Arcion Therapeutics Inc., Baltimore, Md. BioDelivery Sciences International Inc. (NASDAQ:BDSI), Raleigh, N.C. Product: Clonidine (clonidine topical gel) (formerly ARC-4558) Business: Neurology Molecular target: NA …

    Published on 8/18/2014
  • Dolizem diltiazem cream: Development discontinued

    Assembly Biosciences Inc. (NASDAQ:ASMB), New York, N.Y. S.L.A. Pharma AG, Liestal, Switzerland Product: Dolizem diltiazem cream (VEN 307) Business: Gastrointestinal Molecular target: NA Description: Topical formulation …

    Published on 8/18/2014
  • FilmArray Meningitis/Encephalitis Panel: Clinical trial started

    bioMerieux S.A. (Euronext:BIM), Marcy lEtoile, France Product: FilmArray Meningitis/Encephalitis Panel Business: Diagnostic Molecular target: NA Description: In vitro multiplex PCR platform that detects 16 bacterial, …

    Published on 8/18/2014
  • FoundationOne: Clinical trial started

    Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass. Product: FoundationOne Business: Diagnostic Molecular target: NA Description: Laboratory-developed test (LDT) that identifies all somatically altered genes that …

    Published on 8/18/2014
  • Fovista: Phase IIa started

    Archemix Corp., Cambridge, Mass. Ophthotech Corp. (NASDAQ:OPHT), New York, N.Y. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Fovista (formerly E10030) Business: Ophthalmic Molecular target: Platelet …

    Published on 8/18/2014
  • IMAB362: Completed Phase II enrollment

    Ganymed Pharmaceuticals AG, Mainz, Germany Product: IMAB362 Business: Cancer Molecular target: CLND18.2 Description: mAb targeting cell surface antigen CLND18.2 Indication: Treat advanced gastroesophageal cancer …

    Published on 8/18/2014
  • IV CR845: Phase II started

    Cara Therapeutics Inc. (NASDAQ:CARA), Shelton, Conn. Chong Kun Dang Pharmaceutical Corp. (KSE:001630), Seoul, South Korea Maruishi Pharmaceutical Co. Ltd., Osaka, Japan Product: IV CR845 Business: Dermatology Molecular …

    Published on 8/18/2014
  • L-leucine plus metformin: Phase IIa started

    NuSirt Biopharma Inc., Nashville, Tenn. Product: L-leucine plus metformin Business: Endocrine/Metabolic Molecular target: NA Description: Fixed-dose combination of leucine and metformin Indication: Treat Type II …

    Published on 8/18/2014
  • Lexaptepid pegol: Phase IIa started

    Noxxon Pharma AG, Berlin, Germany Product: Lexaptepid pegol (NOX-H94) Business: Hematology Molecular target: Hepcidin Description: L-aptamer hepcidin inhibitor Indication: Treat anemia in erythropoietin (EPO)-…

    Published on 8/18/2014
  • Lirilumab: Completed Phase II enrollment

    Innate Pharma S.A. (Euronext:IPH), Marseille, France Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Lirilumab (BMS-986015, IPH2102) Business: Cancer …

    Published on 8/18/2014
  • LOR-253: Phase Ib start

    Lorus Therapeutics Inc. (TSX:LOR; Pink:LRUSF), Toronto, Ontario Product: LOR-253 (formerly LT-253) Business: Cancer Molecular target: Kruppel-like factor 4 (KLF4) (EZF) Description: Small molecule optimized to increase …

    Published on 8/18/2014
  • MM-302: Phase II started

    Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass. Product: MM-302 Business: Cancer Molecular target: Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (neu) Description: Pegylated liposomal …

    Published on 8/18/2014
  • Olaparib: Phase III started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Olaparib (AZD2281, KU-0059436) Business: Cancer Molecular target: Poly(ADP-ribose) polymerase (PARP) Description: Poly(ADP-ribose) polymerase (PARP) inhibitor …

    Published on 8/18/2014
  • Oral solithromycin: Phase III started

    Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Toyama Chemical Co. Ltd., Tokyo, Japan Product: Oral solithromycin (CEM-101) (formerly OPT-1068) Business: …

    Published on 8/18/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993